Comparing the current results to its competitors, Verrica Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -53.85 %, despite the revenue increase by the most of its competitors of 15.44 %, recorded in the same quarter.
Verrica Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -0.06 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -0.06 %
Verrica Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company competes with major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as compounding facilities, academic institutions, governmental agencies, and public and private research organizations. For YCANTH (VP-102), which targets common warts, competition includes over-the-counter products, cryotherapy, curettage, laser surgery, and other off-label treatments. There are currently no FDA-approved prescription pharmaceutical therapies for common warts. Several companies are developing product candidates for this indication. For VP-315, multiple companies are developing therapies for basal cell carcinoma (BCC) at various clinical stages. The company holds three issued U.S. utility patents related to YCANTH (VP-102), with the earliest expiring in 2037, but acknowledges risks associated with patent expiration and potential competitor design-arounds.
October 2, 2024
In an eye-catching move aimed at recalibrating its strategic trajectory, Verrica Pharmaceuticals Inc. has recently announced a comprehensive restructuring of its commercial organization, a decision necessitated by a sobering year amidst severe market challenges. As the company grapples with a staggering 75.18% decline in its share price year to date significantly outpacing the broader market s 20.99% rise this realignment appears both prudent and imperative for long-term sustainability.The restructuring initiative is designed to substantially reduce the company’s cost structure, thereby enhancing operational efficiencies across sales and marketing. By streamlining its commercial infrastructure, Verrica see...
August 14, 2024
Positive Advances in Basal Cell Carcinoma Treatment: Verrica Pharmaceuticals VP-315 Shows Promising Results In an inspiring stride towards combating Basal Cell Carcinoma (BCC), Verrica Pharmaceuticals recently unveiled positive preliminary topline results from Part 2 of their Phase 2 clinical study of VP-315. This investigational oncolytic peptide-based immunotherapy, aimed at treating patients with BCC, has shown significant promise in its early trials.Basal Cell Carcinoma is the most common form of skin cancer, often resulting in disfiguring lesions and requiring invasive treatments. The development of innovative, non-surgical treatments is crucial for improving patient outcomes and quality of life. Verri...
July 1, 2024
Verrica Pharmaceuticals, a dermatology therapeutics company, has recently announced a litigation settlement with Dormer Laboratories, Inc. The settlement has led to Dormer Labs discontinuing the sale of all cantharidin-containing products into the United States. Cantharidin is a substance derived from blister beetles and is commonly used in the treatment of skin conditions.The settlement comes as a result of a dispute between Verrica Pharmaceuticals and Dormer Laboratories, Inc. regarding the sale and distribution of cantharidin-containing products in the United States. Through their legal proceedings, Verrica Pharmaceuticals has successfully reached an agreement with Dormer Labs, leading to the discontinuat...
May 27, 2024
In recent news, Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) finds itself under the scrutiny of Bragar Eagel and Squire, P.C., a well-respected shareholder rights law firm. The firm has initiated an investigation after the filing of a class action complaint against Verrica, raising questions about the company s management practices and possible breaches of fiduciary duties by its board of directors. This development has significant implications for long-term stockholders, as potential claims against the pharmaceutical company come into focus.The Allegations:Bragar Eagel and Squire s investigation centers around a class period ranging from May 28, 2021, to May 24, 2022. The firm aims to determine whether Verr...
May 15, 2024
Verrica Pharmaceuticals Inc. has announced a significant amendment to its collaboration and license agreement with Japan-based Torii Pharmaceutical Co. Ltd. This strategic modification aims to fund and facilitate a global pivotal Phase 3 clinical trial to study YCANTH for the treatment of common warts. The jointly conducted trial is expected to commence in the first half of 2025. BackgroundCommon warts, caused by the human papillomavirus (HPV), represent a widespread dermatological condition affecting millions worldwide. Despite the prevalence, the market remains underserved with effective and safe treatment options being limited. Verrica Pharmaceuticals has been pioneering the development of YCANTH (canthar...
March 26, 2024
Verrica Pharmaceuticals, a renowned pharmaceutical company, has recently announced that its product YCANTH has received the prestigious New Chemical Entity (NCE) status from the U.S. Food and Drug Administration (FDA). This regulatory milestone grants Verrica a minimum of five years of market exclusivity, paving the way for potential commercial success and furthering their mission to address unmet medical needs. This article aims to outline the facts surrounding this groundbreaking development and shed light on the significance of this achievement for Verrica Pharmaceuticals and its investors.Facts:1. YCANTH, a pharmaceutical product developed by Verrica Pharmaceuticals, has received New Chemical Entity (NCE...
January 29, 2024
Verrica Pharmaceuticals, a leading dermatology therapeutics company, has recently received a significant milestone in its quest to provide medical interventions for skin diseases. The Centers for Medicare and Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica s groundbreaking medication, YCANTH. This marks a crucial step forward in treating molluscum contagiosum, a common skin condition affecting millions worldwide.Promoting Access to Innovative TreatmentMolluscum contagiosum is a viral skin infection characterized by small, raised, and painless lesions on the skin. It most commonly affects children, but can also impact adults, particularly those with weakened immune systems. Until now...
Publicly Traded Peers of Verrica Pharmaceuticals Inc
Verastem Inc Share Performance
+2.29%
30 Days
Verastem Inc
Profile
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Dermata Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing dermatology and skin care products, focusing on innovative treatments for various skin conditions.
Emergent Biosolutions Inc's business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Sources:
Verrica Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Verrica Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
